Since CD30 has already been shown to be a potentially targetable structure, CAR-T-cell research for HL focuses on optimization of lymphodepletion regimens (304), improvement and high-precision engineering of CAR-T cells (305, 306), and the development of combinatorial regimens (307) with agents like PD-1 inhibitors (308) or allo-HSCT (309). Here, TNFRSF8 is linked to Hodgkins lymphoma.